{"id":"W2600359049","doi":"10.1182/blood.v128.22.617.617","title":"Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Bendamustine; Rituximab; Medicine; Venetoclax; Ven; Internal medicine; Chemotherapy regimen; Regimen; Chemotherapy; Chemoimmunotherapy; Follicular lymphoma; Clinical endpoint; Gastroenterology; Oncology; Lymphoma; Leukemia; Randomized controlled trial; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002963984,0.001260533,0.00239241,0.0004140024,0.0003468334,0.0009867657,0.0009023972,0.00131241,0.006699213],"category_scores_gemma":[0.001515492,0.0006577577,0.001615058,0.0004019626,0.0008402101,0.001061142,0.0003614822,0.002613425,0.001126108],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008452841,"about_ca_system_score_gemma":0.001362593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008146107,"about_ca_topic_score_gemma":0.001991284,"domain_scores_codex":[0.9991693,0.0005164056,0.00003764463,0.0001047074,0.00004113468,0.0001308523],"domain_scores_gemma":[0.9990327,0.0002540395,0.0001828949,0.00008214432,0.00006141609,0.0003866664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9602509,0.01268504,0.0009893936,0.0003285197,0.000628721,0.00004412237,0.00004472689,0.0004879435,0.003939052,0.00009531024,0.0009815455,0.01952465],"study_design_scores_gemma":[0.7478881,0.2466438,0.002781691,0.00002887393,0.0004216904,0.00004282701,0.00002094718,0.0003205997,0.0005780666,0.0001603477,0.00109944,0.00001368001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758136,0.004418752,0.001041236,0.000820687,0.000471076,0.01007942,0.003005158,0.0001671632,0.00418287],"genre_scores_gemma":[0.978368,0.002319879,0.002405775,0.001211605,0.0004563641,0.008259327,0.002387615,0.00003170188,0.004559617],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006699213,"threshold_uncertainty_score":0.02241105,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03353409437138315,"score_gpt":0.3008351832060036,"score_spread":0.2673010888346204,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}